Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance

Human Pathology

Volumn 41, Issue 5, 2010, Pages 686-696

  Zhao, Zhong Sheng ^a   Chu, Yong Quan ^b   Ye, Zai Yuan ^a   Wang, Yuan Yu ^a   Tao, Hou Quan ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b First Hospital of Jiaxing   (China)

Author keywords

Gastric cancer; IGF 1; Immunohistochemistry; MMP 11

Indexed keywords

MESSENGER RNA; SOMATOMEDIN C; STROMELYSIN 3;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 11; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77950593512     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.10.010     Document Type: Article

References (34)

1. Wang C.S., Chao T.C., Jan Y.Y., et al. Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J 25 (2002) 792-802
2. Choi S.R., Jang J.S., Lee J.H., et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 51 (2006) 2081-2086
3. Shim K.N., Jung S.A., Joo Y.H., and Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 42 (2007) 120-128
4. Motrescu E.R., and Rio M.C. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem 389 (2008) 1037-1041
5. Deng H., Guo R.F., Li W.M., et al. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun 326 (2005) 274-281
6. Basset P., Bellocq J.P., Wolf C., et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348 (1990) 699-704
7. Kren L., Goncharuk V.N., Krenova Z., et al. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol 42 (2006) 16-19
8. Thorns V., Walter G.F., and Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 23 (2003) 3937-3944
9. Wasenius V.M., Hemmer S., Kettunen E., et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9 (2003) 68-75
10. Mellick A.S., Blackmore D., Weinstein S.R., and Griffiths L.R. An assessment of MMP and TIMP gene expression in cell lines and stroma-tumour differences in microdissected breast cancer biopsies. Tumour Biol 24 (2003) 258-270
11. Pedersen G., Saermark T., Kirkegaard T., and Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol 155 (2009) 257-265
12. Hegedus L., Cho H., Xie X., and Eliceiri G.L. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 216 (2008) 480-485
13. Wlodarczyk J., Stolte M., and Mueller J. E-cadherin, beta-catenin and stromelysin-3 expression in de novo carcinoma of the colorectum. Pol J Pathol 52 (2001) 119-124
14. Mueller J., Steiner C., and Hofler H. Stromelysin-3 expression in noninvasive and invasive neoplasms of the urinary bladder. Hum Pathol 31 (2000) 860-865
15. Mueller J., Brebeck B., Schmalfeldt B., et al. Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch 437 (2000) 618-624
16. Franciosi C.M., Piacentini M.G., et al. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology 50 (2003) 297-300
17. Chen P.P., Li W.J., Wang Y., et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE 2 (2007) e534
18. Lee H.S., Lee H.K., Kim H.S., Yang H.K., and Kim W.H. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200 (2003) 39-46
19. Lee H.S., Lee H.K., Kim H.S., Yang H.K., Kim Y.I., and Kim W.H. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 92 (2001) 1427-1434
20. Zhang D., Salto-Tellez M., Putti T.C., et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16 (2003) 79-84
21. Kolev Y., Uetake H., Iida S., et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14 (2007) 2738-2747
22. Song L.B., Liao W.T., Mai H.Q., et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242 (2006) 258-265
23. Fiorentino M., Fu L., and Shi Y.B. Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency. Int J Mol Med 23 (2009) 389-397
24. Motrescu E.R., Blaise S., Etique N., et al. Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 27 (2008) 6347-6355
25. Perigny M., Bairati I., Harvey I., et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129 (2008) 226-231
26. Duffy M.J., Maguire T.M., Hill A., et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2 (2000) 252-257
27. Sharma R., Chattopadhyay T.K., Mathur M., and Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 67 (2004) 300-309
28. Massi D., Franchi A., Ketabchi S., et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol 34 (2003) 80-88
29. Kasper G., Reule M., Tschirschmann M., et al. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer 7 (2007) 12
30. Ito Y., Yoshida H., Kakudo K., et al. Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology 38 (2006) 421-425
31. Noel A., Boulay A., Kebers F., et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19 (2000) 1605-1612
32. Nedic O., Malenkovic V., Nikolic J.A., and Baricevic I. Insulin-like growth factor I (IGF-I) as a sensitive biomarker of catabolism in patients with gastrointestinal diseases. J Clin Lab Anal 21 (2007) 335-339
33. Pham T.M., Fujino Y., Kikuchi S., et al. A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer 43 (2007) 1611-1616
34. Jiang Y., Wang L., Gong W., et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 21 (2004) 755-764